|
業務類別
|
Biotechnology |
|
業務概覽
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with apotential best-in-class mechanism of action. |
| 公司地址
| 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001 |
| 電話號碼
| +1 646 661-7661 |
| 傳真號碼
| +1 646 661-4027 |
| 公司網頁
| https://www.ovidrx.com |
| 員工數量
| 23 |
| Ms. Margaret Alexander |
Chief Executive Officer and Director |
美元 484.42K |
12/11/2025 |
| Mr. Jeffrey A. Rona |
Principal Accounting Officer, Chief Business Officer and Chief Financial Officer |
美元 492.13K |
22/05/2025 |
|
|
| Dr. Stelios Papadopoulos,PhD |
Director |
05/03/2025 |
| Mr. Bart Friedman, J.D. |
Lead Independent Director |
22/05/2025 |
| Dr. Kevin Fitzgerald, PhD |
Independent Director |
22/05/2025 |
| Mr. Jeremy M. Levin, D.Phil.,M.B. |
Executive Chairman of the Board |
12/11/2025 |
| Ms. Margaret Alexander |
Chief Executive Officer and Director |
12/11/2025 |
| Ms. Barbara G. Duncan |
Independent Director |
22/05/2025 |
| Dr. Karen Bernstein, PhD |
Independent Director |
22/05/2025 |
|
|
|
|
